Acquiring Paul O’Neill for Roberto Kelly in November 1992 was the first big move of Gene Michael’s tenure. O’Neill fondly remembers the former Yankees GM. As told to The Post: Gene was the first person I talked to when I was traded to the Yankees and the reason I came to New York. I always...
NYS Entity Status
NYS Filing Date
JUNE 21, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - MICHAEL WILLIAM PAUL LTD.
AROUND THE WEB
- Paul O’Neill: Gene Michael gave me the opportunity of a lifetime
By Paul O'Neill - Friday Sep 8, 2017
- Sunday Routine: How Paul Rabil, Lacrosse Player, Spends His Sundays
By ANDREW COTTO - Friday Jul 28, 2017
The athlete, entrepreneur and Williamsburg, Brooklyn, resident spends a lot of time by himself, reading, writing, working, and sometimes even painting.
- Michael K. Williams Is More Than Omar From ‘The Wire’
By NOAH REMNICK - Friday Jun 30, 2017
Mr. Williams has made a career of bringing nuance and contrast to his roles, inspired by the swaggering characters he grew up with in East Flatbush.
- ‘Morning Joe:’ Scarborough Calls Trump’s NY Times Interview ‘William Faulkner on Acid’ (Video)
By Ashley Boucher, provided by
- Thursday Jul 20, 2017
Morning Joe” host Joe Scarborough said Thursday that President Donald Trump’s rambling, stream of consciousness interview with the New York Times sounds like “William Faulkner on acid.“I mean the sentences just keep going on, but they’re garbled and make absolutely no sense,” the host said, referring to the Nobel Prize laureate’s distinctive writing style.“Well, John McCain, obviously a giant in Washington, D.C., but he’s been a giant in American life for a very long time and he served his entire adult life for the American people,” Scarborough said.
- Near The East River, Plans Emerge For NY’s Next Life Science Center
By Ben Fidler - Monday Aug 21, 2017
At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]
- FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
By Ben Fidler - Tuesday Aug 29, 2017
The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]